Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 31;19(3):1711–1718. doi: 10.3892/etm.2019.8399

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Overexpression of FGF9 leads to development of cisplatin resistance in LoVo cells. (A) Compared with parental LoVo cells (LoVo/parental), cisplatin resistant LoVo cells (LoVo/cisplatin) were less sensitive to cisplatin treatment. ***P<0.001 vs. LoVo/parental. (B) Protein expression for FGF9 and β-catenin in LoVo/cisplatin cells increased and APC protein expression decreased compared with LoVo/parental cells. (C) Quantitative analysis of FGF9, APC and β-catenin protein expression from panel B. (D) Silencing of FGF9 enhanced cisplatin-induced cytotoxicity in LoVo/cisplatin cells. **P<0.01 vs. control siRNA. FGF9, fibroblast growth factor 9; APC, adenomatous polyposis coli; siRNA, small interfering RNA.